Mounjaro overdose: treatment, symptoms and when to act

You've injected more than prescribed, here's what happens next

Picture this: you reach for your Mounjaro pen on the wrong day, or you accidentally use a dose you'd already taken, and it's only afterwards that you realise the error. This is the situation our prescribers hear about most weeks, and the right response is always the same: call for clinical help without delay, even if you feel fine right now.

Tirzepatide has a long half-life (around five days) which means whatever has entered your system will remain active for much longer than most medicines. Symptoms of an excess dose may not peak immediately. Nausea and vomiting are the most common early signs. In people who take other glucose-lowering medicines alongside Mounjaro, hypoglycaemia (low blood sugar) is a real risk and can develop quietly before it becomes obvious. Symptoms of low blood sugar include shakiness, sweating, confusion, and in severe cases, loss of consciousness.

The NHS patient information for tirzepatide advises contacting a doctor or going to A&E straight away if you think you have taken too much. If the situation feels urgent (someone is unconscious, fitting, or unable to stay awake) call 999. Otherwise, NHS 111 can assess severity and direct you to the right level of care. Keep the pen or its packaging with you so healthcare staff can see the strength and lot number.

What treatment looks like in practice: supportive care and monitoring

There is no reversal agent or antidote for tirzepatide. That is not unusual (most GLP-1 receptor agonists lack one) and it does not mean nothing can be done. Clinical management is supportive, meaning treatment is matched to whichever symptoms appear and how severe they are.

For gastrointestinal symptoms, anti-nausea medicines can reduce distress; intravenous fluids may be given if vomiting has caused dehydration. Blood glucose is monitored closely, especially over the first 24–48 hours, and corrected if hypoglycaemia develops. Healthcare teams will also watch for signs of pancreatitis (a known but infrequent serious side effect highlighted in the MHRA's January 2026 Drug Safety Update) because any condition causing severe stomach pain that reaches the back warrants investigation in this context.

Because the medicine stays active for roughly five days, observation does not end when the acute symptoms settle. If you are discharged from hospital or assessed at home, you should have a clear plan for who to contact if symptoms return or worsen. If you are currently being treated through a regulated service, informing your prescriber matters: they need to know what happened before your next scheduled dose.

For broader context on what to eat alongside treatment (which can influence how well you tolerate the medicine) the guide to eating on Mounjaro covers protein, hydration and fibre in detail.

The doses involved: why accidental double-dosing is the usual scenario

Intentional overdose is rare with tirzepatide. The far more common picture involves an accidental second injection, a missed entry in a tracking app, a partner administering a dose the patient had already taken, or confusion during a transition between dose strengths. If you want a full breakdown of how the medicine works at each stage, our guide to tirzepatide treatment explains the mechanism and what to expect as the drug builds up in your system. The tirzepatide titration schedule starts at 2.5 mg and steps up in 4-week stages; the pen format means each click delivers a fixed quantity, so a genuine double dose at any strength is a definite clinical event, not just a possibility.

Higher strengths carry proportionally greater risk of adverse effects from accidental doubling, simply because more active drug enters circulation. A second 2.5 mg injection at the start of treatment is a different situation from a second 15 mg injection, even if both deserve prompt clinical attention. The full overview of Mounjaro for weight loss explains the titration schedule and what each dose step is designed to achieve, and our dedicated page on Mounjaro treatment covers the broader clinical picture of how the medicine is used in practice.

Keeping a written or app-based injection log (noting the date, time and strength) is the single most practical step to prevent accidental re-dosing. Some people use a calendar reminder immediately after injecting. It takes ten seconds and removes the risk entirely.

After an overdose: returning to treatment safely

Provided there are no ongoing complications, most people can return to their prescribed tirzepatide schedule once a clinician confirms it is safe to do so. Timing the next dose correctly is important, returning too soon extends the period of elevated drug exposure. Your prescriber, not the original injection day, sets the restart point.

If severe side effects occurred, a prescriber may choose to delay resuming, return to a lower dose temporarily, or review whether any other medicines you take need adjusting. This is particularly relevant if low blood sugar was a feature, as that points to an interaction requiring fresh assessment. It is also worth knowing that some people notice skin changes around the injection site or more broadly during treatment, so if that applies to you, our pages on Mounjaro skin rash treatment and Mounjaro skin sensitivity treatment explain what to look out for and when to seek advice.

If you are considering starting treatment for the first time and want to understand what clinical oversight involves, checking your eligibility through a free consultation is the right starting point. At nume, every repeat order is clinically re-reviewed before dispatch, no automation, no auto-renewals. You can read more about the clinical team behind those reviews on our prescribers' page.

For any concerns about a side effect that is not an emergency but needs attention, the contact page connects you to aftercare seven days a week. Suspected adverse reactions can also be submitted directly to the MHRA via the Yellow Card scheme, that reporting helps regulators track the real-world safety profile of newer medicines.